drugset
drugset / Trial / NCT06235437

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141

NCT06235437 ↗

Phase 1 Recruiting 21 enrolled Ascendo Biotechnology Co., Ltd.
NaSequentialOpen-labelTreatment

Summary

This is a Phase I study designed to evaluate if ASD141 is safe, tolerable, and efficacious in participants with advanced solid tumors.

Timeline

Start
2024-08-29
Primary completion
2026-12
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ASD141 Unknown 0.01 mg/kg Intravenous
Subject ASD141 Unknown 0.03 mg/kg Intravenous
Subject ASD141 Unknown 0.1 mg/kg Intravenous
Subject ASD141 Unknown 0.3 mg/kg Intravenous
Subject ASD141 Unknown 1 mg/kg Intravenous
Subject ASD141 Unknown 3 mg/kg Intravenous
Subject ASD141 Unknown 10 mg/kg Intravenous
Subject ASD141 Unknown 30 mg/kg Intravenous

Indications

metastatic neoplasm